MAP1LC3A and hepatocellular carcinoma: In keeping with the multivariate Cox model, TIPRL significantly influenced the OS of patients in both a whole population of HCC (HR 1.42, logrank p = 0.05) and sorafenib-treated patients (HR 3, logrank p = 0.06), which is currently the only systemic agent approved for use in HCCs; however, MAP1LC3A (HR 0.93, logrank p = 0.7; HR = 1.1, logrank p = 0.9) and PROM1 (CD133; HR 0.8, logrank p = 0.3; HR 1, logrank p = 0.9) did not show significant influence (Fig. 2b–d).